{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"BioNTech SE"},"Symbol":{"label":"Symbol","value":"BNTX"},"Address":{"label":"Address","value":"AN DER GOLDGRUBE 12, MAINZ, D-55131, Germany"},"Phone":{"label":"Phone","value":"+49 613190840"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Europe"},"CompanyDescription":{"label":"Company Description","value":"BioNTech SE is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product."},"CompanyUrl":{"label":"Company Url","value":"https://www.biontech.de"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Özlem Türeci","title":"Chief Medical Officer"},{"name":"Sierk Poetting","title":"Chief Operating Officer"},{"name":"Ugur Sahin","title":"Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}